ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

15 Health Benefits of Chia Seeds, According to Science

Tangerine Oil: A Citrusy Essential Oil With Well-Rounded Uses

Magnesium Deficiency Raises Your Risk of Many Chronic Ailments

Resveratrol supplementation improves arterial stiffness in type 2 diabetics

CoQ10's Potential Capabilities for Your Health

Testosterone replacement therapy associated with improved urinary, sexual function

How Can Melatonin Benefit You?

Cloves: Boost Your Immune System the Sweet and Spicy Way

The Many Potential Health Benefits of Curcumin

8 Chia Seed Recipes

 
Print Page
Email Article

UAMS Reports Bone Loss From Oral Diabetes Drug

  [ 30 votes ]   [ Discuss This Article ]
www.ProHealth.com • October 9, 2003


LITTLE ROCK, Ark., Oct. 8 /PRNewswire/ -- Scientists at the University of Arkansas for Medical Sciences (UAMS) report in the journal Endocrinology that a widely used oral drug for type 2 diabetes may pose a significant risk of bone loss.

The researchers report that in a laboratory study the anti-diabetic compound rosiglitazone (known as Avandia), caused a significant decrease in total body bone mineral density, suggesting that Avandia therapy may pose a significant risk of adverse skeletal effects in humans.

"Avandia is an FDA-approved and clinically successful treatment for type 2 diabetes. Our findings suggest that doctors should watch the skeletons of patients who use this drug, especially older patients, because their patients may be at increased risk of bone loss over time," said lead researcher Beata Lecka-Czernik, Ph.D., a molecular and cell biologist.

An estimated 16 million Americans have type 2 diabetes, which results from insulin resistance, a condition in which the body does not properly use insulin, along with relative insulin deficiency. The disease typically develops in people over the age of 40. Rosiglitazone, a very effective anti-diabetic agent that reduces insulin resistance, has had federal approval since 1999.

The National Institute on Aging funded the research at UAMS with a five-year, $925,000 grant. Physiologists and endocrinologists Larry J. Suva, Ph.D., and Dana Gaddy, Ph.D., are co-investigators. Lecka-Czernik is a member of the Donald W. Reynolds Department of Geriatrics and Suva and Gaddy are members of the faculty of the Departments of Orthopaedic Surgery and Physiology and Biophysics, all in the UAMS College of Medicine. All three researchers are members of the Arkansas Cancer Research Center at UAMS. S. O. Rzonca and D. C. Montague, research assistants who conducted the experiment and technical analyses, are co-authors of the article in Endocrinology.

The UAMS scientists used micro-computed tomography to analyze the bones of healthy mice that received doses of rosiglitazone over seven weeks. The doses that mice received were the same doses mice received in earlier studies that demonstrated the compound's effectiveness for type 2 diabetes. The researchers next plan to test the effects of the drug on mice and rats with diabetes. Lecka-Czernik also has a grant for the follow-up study of $300,000
for three years from the American Diabetes Association.

A gift of $288,000 from the Roy and Christine Sturgis Charitable Trust in 2002 enabled UAMS to purchase the sophisticated bone analysis equipment used in the study.

The journal Endocrinology is published by The Endocrine Society. UAMS is the leading biomedical research institution in Arkansas and the home of the Donald W. Reynolds Center on Aging as well as the Donald W. Reynolds Department of Geriatrics.

SOURCE: University of Arkansas for Medical Sciences
Web Site: http://www.uams.edu



Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength Optimized Curcumin Longvida® Vitamin D3 Extreme™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

The Super Antioxidant for Brain, Joint and Heart Health The Super Antioxidant for Brain, Joint and Heart Health
Pioneer Scientists Uncover a Revolutionary Neuroprotective Supplement for Nerve Health Pioneer Scientists Uncover a Revolutionary Neuroprotective Supplement for Nerve Health
Complete and Natural Menopause Relief Complete and Natural Menopause Relief
Nutrients to Combat the Modern Stress Epidemic Nutrients to Combat the Modern Stress Epidemic
Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map